(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(-3.38%) $79.16
(-3.11%) $1.929
(0.94%) $2 324.50
(0.92%) $26.90
(1.30%) $960.50
(-0.29%) $0.934
(-0.42%) $11.05
(-0.15%) $0.799
(-0.48%) $93.00
0.00% € 23.40
Live Chart Being Loaded With Signals
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo...
Stats | |
---|---|
Tagesvolumen | 32.00 |
Durchschnittsvolumen | 520.00 |
Marktkapitalisierung | 280.57M |
EPS | €0 ( 2024-04-07 ) |
Nächstes Ertragsdatum | ( €0 ) 2024-05-14 |
Last Dividend | €0.490 ( 2023-06-29 ) |
Next Dividend | €0 ( N/A ) |
P/E | 18.72 |
ATR14 | €0 (0.00%) |
PharmaSGP Holding SE Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
PharmaSGP Holding SE Finanzdaten
Annual | 2022 |
Umsatz: | €85.82M |
Bruttogewinn: | €76.79M (89.48 %) |
EPS: | €1.000 |
FY | 2022 |
Umsatz: | €85.82M |
Bruttogewinn: | €76.79M (89.48 %) |
EPS: | €1.000 |
Financial Reports:
No articles found.
PharmaSGP Holding SE Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0.490 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.450 | 2022-06-16 |
Last Dividend | €0.490 | 2023-06-29 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | €0.940 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.99 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.90 | |
Div. Directional Score | 8.25 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
VVD.DE | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% | |
EVK.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
OMV.DE | Ex Dividend Knight | 2023-06-06 | Annually | 0 | 0.00% | |
AMG.DE | Ex Dividend Knight | 2023-08-17 | Quarterly | 0 | 0.00% | |
HAW.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
RIO1.DE | Ex Dividend Knight | 2023-08-10 | Semi-Annually | 0 | 0.00% | |
BST.DE | Ex Dividend Junior | 2023-09-14 | Sporadic | 0 | 0.00% | |
JNJ.DE | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
TA1.DE | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
DEF.DE | Ex Dividend Knight | 2023-07-24 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.154 | 1.500 | 6.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.114 | 1.200 | 6.20 | 7.44 | [0 - 0.3] |
returnOnEquityTTM | 0.451 | 1.500 | 6.10 | 9.15 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.56 | 0.800 | 2.21 | 1.766 | [1 - 3] |
quickRatioTTM | 2.05 | 0.800 | 2.66 | 2.13 | [0.8 - 2.5] |
cashRatioTTM | 1.546 | 1.500 | 2.52 | 3.78 | [0.2 - 2] |
debtRatioTTM | 0.00766 | -1.500 | 9.87 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 5.89 | 1.000 | 8.93 | 8.93 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.18 | 2.00 | 9.27 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.12 | 2.00 | 8.94 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0275 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.906 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.246 | 1.000 | 7.08 | 7.08 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 25.94 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.742 | 0.800 | 8.39 | 6.71 | [0.5 - 2] |
Total Score | 11.60 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 18.72 | 1.000 | 8.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.451 | 2.50 | 7.49 | 9.15 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.12 | 2.00 | 9.29 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.09 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.18 | 2.00 | 9.27 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.268 | 1.000 | 5.81 | 0 | [0.1 - 0.5] |
Total Score | 4.90 |
PharmaSGP Holding SE
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.